Compare TWO & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWO | ABUS |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 888.5M |
| IPO Year | 2009 | N/A |
| Metric | TWO | ABUS |
|---|---|---|
| Price | $13.52 | $4.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $12.31 | $5.00 |
| AVG Volume (30 Days) | ★ 3.4M | 1.6M |
| Earning Date | 02-02-2026 | 11-13-2025 |
| Dividend Yield | ★ 9.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $532,207,999.00 | $14,606,000.00 |
| Revenue This Year | N/A | $125.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 498.21 | 116.64 |
| 52 Week Low | $9.30 | $2.71 |
| 52 Week High | $14.28 | $5.10 |
| Indicator | TWO | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 69.01 | 39.44 |
| Support Level | $13.12 | $3.99 |
| Resistance Level | $13.83 | $4.25 |
| Average True Range (ATR) | 0.59 | 0.22 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 77.41 | 37.02 |
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. The majority of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.